|
Name |
Dactylarin
|
Molecular Formula | C16H16O6 | |
IUPAC Name* |
(2R,3S)-2,3,8-trihydroxy-6-methoxy-3-methyl-2,4-dihydro-1H-anthracene-9,10-dione
|
|
SMILES |
C[C@@]1(CC2=C(C[C@H]1O)C(=O)C3=C(C2=O)C=C(C=C3O)OC)O
|
|
InChI |
InChI=1S/C16H16O6/c1-16(21)6-10-8(5-12(16)18)15(20)13-9(14(10)19)3-7(22-2)4-11(13)17/h3-4,12,17-18,21H,5-6H2,1-2H3/t12-,16+/m1/s1
|
|
InChIKey |
AAHQQIFXAQHGBD-WBMJQRKESA-N
|
|
Synonyms |
Dactylarin; Altersolanol B; 22350-90-9; (2R,3S)-2,3,8-trihydroxy-6-methoxy-3-methyl-2,4-dihydro-1H-anthracene-9,10-dione; 3,7-dihydroxy-3',5-dimethoxy-5'-methylspiro[3H-1-benzofuran-2,4'-cyclohexa-2,5-diene]-1'-one; CHEMBL2011669; SCHEMBL23522406; DTXSID70176887; 9,10-Anthracenedione, 1,2,3,4-tetrahydro-2,3,5-trihydroxy-7-methoxy-2-methyl-, (2S-cis)-; 3,7-Dihydroxy-2',5-dimethoxy-6'-methylspiro(benzofuran-2(3H),1'-(2,5)cyclohexadien)-4'-one; 9,10-Anthracenedione, 1,2,3,4-tetrahydro-2,3,5-trihydroxy-7-methoxy-2-methyl-, (2S,3R)-
|
|
CAS | 22350-90-9 | |
PubChem CID | 161389 | |
ChEMBL ID | CHEMBL2011669 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 304.29 | ALogp: | 0.9 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.725 |
Caco-2 Permeability: | -5.215 | MDCK Permeability: | 0.00000851 |
Pgp-inhibitor: | 0.021 | Pgp-substrate: | 0.995 |
Human Intestinal Absorption (HIA): | 0.03 | 20% Bioavailability (F20%): | 0.317 |
30% Bioavailability (F30%): | 0.043 |
Blood-Brain-Barrier Penetration (BBB): | 0.022 | Plasma Protein Binding (PPB): | 94.32% |
Volume Distribution (VD): | 0.75 | Fu: | 9.76% |
CYP1A2-inhibitor: | 0.614 | CYP1A2-substrate: | 0.905 |
CYP2C19-inhibitor: | 0.025 | CYP2C19-substrate: | 0.162 |
CYP2C9-inhibitor: | 0.189 | CYP2C9-substrate: | 0.646 |
CYP2D6-inhibitor: | 0.103 | CYP2D6-substrate: | 0.207 |
CYP3A4-inhibitor: | 0.175 | CYP3A4-substrate: | 0.253 |
Clearance (CL): | 16.107 | Half-life (T1/2): | 0.889 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.272 |
Drug-inuced Liver Injury (DILI): | 0.48 | AMES Toxicity: | 0.557 |
Rat Oral Acute Toxicity: | 0.077 | Maximum Recommended Daily Dose: | 0.292 |
Skin Sensitization: | 0.9 | Carcinogencity: | 0.035 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.529 |
Respiratory Toxicity: | 0.442 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000880 | 0.706 | D07MGA | 0.304 | ||||
ENC003587 | 0.690 | D01XWG | 0.266 | ||||
ENC000958 | 0.690 | D07VLY | 0.260 | ||||
ENC003511 | 0.667 | D0C9XJ | 0.260 | ||||
ENC004679 | 0.600 | D01XDL | 0.256 | ||||
ENC001504 | 0.545 | D0C1SF | 0.253 | ||||
ENC000783 | 0.544 | D08LTU | 0.237 | ||||
ENC003228 | 0.535 | D0N1FS | 0.234 | ||||
ENC005543 | 0.534 | D0R9WP | 0.233 | ||||
ENC005208 | 0.532 | D08NQZ | 0.233 |